Martin W. Brechbiel
Radiation Oncology Branch
National Cancer Institute
United States of America
Dr. Brechbiel joined the NCI in 1983 and received his Ph.D. from American University in 1988. He was appointed Acting Section Chief of the Radioimmune & Inorganic Chemistry Section in 1997. Dr. Brechbiel became the tenured Section Chief of the Radioimmune & Inorganic Chemistry Section in 2001. His research interests span the array of possible uses of both diagnostic (SPECT/PET) and therapeutic radionuclides (beta and alpha emitters), paramagnetic metal ions (Gd(III) MRI), as well as applications of nanoparticles and the development of dyes suitable for use in Optical Imaging with an emphasis on combinations of imaging and therapy modalities. His research includes synthesis of novel macrocyclic polyamine molecules, synthesis of chelating agents for the sequestration of radioactive metal ions, synthesis of novel chelating agents for the creation of new chemotherapeutics, synthesis of multi-modality imaging and therapy agents multi-targeted therapy and imaging of residual intraperitoneal disease (e.g., ovarian, colorectal, pancreatic cancer), and the execution of the pre-clinical studies designed to facilitate the potential translation of all of the above into clinical trail evaluation.
1) Radiochemistry 2) Conjugation Chemistry 3) Targeted Radiation Therapy 4) Imaging 5) -emitter Therapy 6) Nanotechnology 7) Radiolabeled Monoclonal Antibodies for Diagnosis and Therapy.